PPIs can be taken for years without consequences

long-term therapy is linked to B12 and magnesium deficiency, increased fracture and C. difficile infection risk. Prescriptions must be justified, and duration reviewed.

esomeprazole is stronger than omeprazole

40 mg esomeprazole is roughly equivalent to 40 mg omeprazole but more pharmacokinetically stable. The advantage is predictability, not «power».

PPIs cure the cause of reflux

PPIs suppress acid but do not eliminate the cause. After withdrawal, symptoms often return.

Esomeprazole

Drugs for peptic ulcer and GORD. Proton pump inhibitors

ATC code: A02BC05 (Esomeprazole)

Brand names

Nexium, Nexium 24HR

Mechanism of action

The S-enantiomer of omeprazole, specifically and irreversibly inhibits the H+/K+-ATPase (proton pump) of gastric parietal cells. Reduces basal and stimulated hydrochloric acid secretion by 80–95% with daily dosing. The advantage over omeprazole is more consistent pharmacokinetics: the S-enantiomer is less dependent on CYP2C19 metabolism and less affected by genetic variability. With daily dosing, a steady antisecretory effect is reached by days 3–5.

Indications

GERD pharmacological treatment

First line

First-line therapy for GERD in adults and adolescents. CG184 (2014, updated 2019) and 2022 recommend PPIs as the baseline GERD therapy, with dose chosen by esophagitis severity. Erosive esophagitis is treated for 8 weeks, non-erosive disease for 4 weeks with reassessment. Esomeprazole shows efficacy comparable to other PPIs at equivalent doses; at 40 mg it outperforms omeprazole 20 mg in healing of severe erosive esophagitis.

After the course, the patient attempts withdrawal or switches to on-demand dosing. Continuous use beyond 8 weeks is reviewed every 6–12 months.

Sources

Helicobacter pylori infection

First line

Esomeprazole is one of the PPIs used in H. pylori eradication. Maastricht VI/Florence 2022 and 2017 recommend triple or bismuth quadruple therapy for 14 days. Esomeprazole 40 mg twice daily within the regimen provides acid suppression that supports antibiotic activity and concentration stability in the stomach.

Sources

Peptic ulcer disease

First line

Esomeprazole is used for gastric and duodenal ulcers in adults. Standard dose 20–40 mg daily for 4–8 weeks. PPIs accelerate healing and reduce recurrence. In H. pylori-associated ulcer, esomeprazole is part of eradication therapy. In NSAID-related ulcers, the NSAID is discontinued and a PPI course is given with reassessment in 4–8 weeks.

Sources

Barrett esophagus

First line

In Barrett esophagus, PPIs are prescribed lifelong to suppress acid reflux and reduce metaplasia progression. 2022 supports continuous PPI therapy in confirmed Barrett esophagus. Adenocarcinoma prevention data are observational; randomized evidence of cancer risk reduction is lacking, but reflux control remains standard practice.

Sources

ACG: ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (2022)

Functional dyspepsia

Not recommended

Long-term PPI therapy for functional dyspepsia without H. pylori-associated gastritis, esophagitis or other indications is not clinically justified. CG184 recommends reassessing the need to continue after 4 weeks; if there is no clear effect, the drug is discontinued. PPI use «just in case» for general epigastric heaviness is in the overuse category.

Sources

NICE: Gastro-oesophageal reflux disease and dyspepsia in adults (CG184) (2019)

PPI for NSAID gastric prophylaxis in low-risk patients

Not recommended

PPI prophylaxis is not indicated in patients without risk factors for NSAID-induced gastropathy. Risk factors: age ≥ 65, history of peptic ulcer, history of GI bleeding, concurrent glucocorticoids or anticoagulants, high-dose or combined NSAID use, chronic kidney disease. Routine PPI «cover» without these factors is an overuse category.

Sources

ACG: ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (2022)

Practical notes

Timing and administration

Taken 30–60 minutes before a meal, usually half an hour before breakfast. Fasting absorption is maximal, and parietal cell activation coincides with the peak of acid production. Capsules and tablets are swallowed whole without chewing so the enteric coating ensures small intestinal absorption.

Monitoring

With long-term use (over 1 year), monitor serum magnesium and vitamin B12 annually. In older patients and in osteoporosis, assess bone density and consider calcium and vitamin D adjustment. After 4–8 weeks of treatment for GERD or peptic ulcer, evaluate response and consider step-down or withdrawal.

Special situations

Abrupt withdrawal after prolonged therapy can cause rebound hyperacidity with return of heartburn in 2–7 days – even in patients without prior symptoms. Tapering is gradual: half-dose, every other day, then on-demand H2 blockers. Co-administration with clopidogrel does not affect cardiovascular outcomes per the COGENT RCT; routine PPI withdrawal during dual antiplatelet therapy is not warranted.

Drug interactions

Reduces absorption of drugs that require an acidic gastric environment: ketoconazole, itraconazole, atazanavir, erlotinib, iron preparations. With high-dose methotrexate – prolonged elimination and increased toxicity. Not combined with rilpivirine.

Drug–nutrient interactions

Vitamin B12

Long-term (over 2 years) suppression of gastric secretion reduces release of B12 from dietary proteins, leading to subclinical or clinical deficiency in some patients. Annual serum B12 monitoring is recommended for continuous therapy beyond 2 years; oral or parenteral replacement is prescribed at levels below 200 pg/mL.

Source: UpToDate: Esomeprazole: Drug information (2024)

Vitamin B12

PPIs reduce gastric acidity and impair release of dietary B12 from proteins. Long-term use (>2 years) raises B12 deficiency risk 1.5–2 fold. Check B12 levels in PPI courses longer than 12 months, especially in the elderly.

Source: FDA: FDA Drug Safety Communication: PPIs and vitamin B12 deficiency (2010)

Calcium

Calcium carbonate absorption is acid-dependent, and long-term PPI use lowers its bioavailability. Meta-analyses link long-term (> 1 year) PPI use to a modest increase in hip and vertebral fracture risk, mainly in older adults. For PPI users at osteoporosis risk, organic calcium salts (citrate) that do not require an acidic environment are preferred.

Source: UpToDate: Esomeprazole: Drug information (2024)

Iron

Iron salts (sulfate, fumarate) require gastric acid to convert to Fe2+ and be absorbed. On PPI therapy their bioavailability falls by 20–50%. In iron-deficiency anemia in PPI users, parenteral forms or chelated iron are preferred.

Safety

Contraindications

Hypersensitivity to esomeprazole or substituted benzimidazoles
Co-administration with rilpivirine
Age under 1 year for most formulations

Serious adverse effects

Acute interstitial nephritis
Hypomagnesemia with seizures and arrhythmias on long-term therapy
Anaphylaxis (rare)
Subacute cutaneous lupus erythematosus
Increased risk of Clostridioides difficile infection

Common adverse effects

Headache
Diarrhea, constipation, flatulence
Nausea, abdominal discomfort
Dry mouth

Uncommon adverse effects

Rash, pruritus
Insomnia, dizziness
ALT/AST increase
Peripheral edema

PregnancyFDA B

FDA category B. Large cohort studies show no increased risk of congenital malformations. During pregnancy, used on indication, preferably after the first trimester, at the minimum effective dose. Alternatives: antacids and H2 blockers for episodic symptoms.

Breastfeeding

Passes into breast milk in minimal amounts. LactMed classifies it as compatible with breastfeeding. Monitor the infant for gastrointestinal symptoms.

Frequently asked

What is Esomeprazole used for?

Esomeprazole is evaluated for the following indications with varying evidence strength: GERD pharmacological treatment (evidence tier A), Peptic ulcer disease (evidence tier A), Helicobacter pylori infection (evidence tier A). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Esomeprazole?

Common side effects of Esomeprazole (≥ 1 in 100): Headache, Diarrhea, constipation, flatulence, Nausea, abdominal discomfort, Dry mouth. See the Safety section for uncommon and serious reactions.

Is Esomeprazole safe during pregnancy?

FDA category B. FDA category B. Large cohort studies show no increased risk of congenital malformations. During pregnancy, used on indication, preferably after the first trimester, at the minimum effective dose. Alternatives: antacids and H2 blockers for episodic symptoms.

Is Esomeprazole compatible with breastfeeding?

Passes into breast milk in minimal amounts. LactMed classifies it as compatible with breastfeeding. Monitor the infant for gastrointestinal symptoms.

Who should not take Esomeprazole?

Esomeprazole is contraindicated in: Hypersensitivity to esomeprazole or substituted benzimidazoles; Co-administration with rilpivirine; Age under 1 year for most formulations. Full list in the Safety section.

Esomeprazole

Mechanism of action

Indications

GERD pharmacological treatment

Helicobacter pylori infection

Peptic ulcer disease

Barrett esophagus

Functional dyspepsia

PPI for NSAID gastric prophylaxis in low-risk patients

Practical notes

Timing and administration

Monitoring

Special situations

Drug interactions

Drug–nutrient interactions

Vitamin B12

Vitamin B12

Calcium

Iron

Safety

Contraindications

Serious adverse effects

Common adverse effects

Uncommon adverse effects

PregnancyFDA B

Breastfeeding

Frequently asked

Common myths

Magnesium